Prevalence and Economic Burden of Fuchs Endothelial Corneal Dystrophy in the Medicare Population in the United States.
Journal
Cornea
ISSN: 1536-4798
Titre abrégé: Cornea
Pays: United States
ID NLM: 8216186
Informations de publication
Date de publication:
31 Oct 2023
31 Oct 2023
Historique:
received:
17
07
2023
accepted:
23
09
2023
medline:
31
10
2023
pubmed:
31
10
2023
entrez:
31
10
2023
Statut:
aheadofprint
Résumé
The aim of this study was to assess the prevalence and economic burden of Fuchs endothelial corneal dystrophy (FECD) in patients older than 65 years in the United States. A retrospective analysis of the Medicare data reported to the Vision and Eye Health Surveillance System including patients diagnosed with FECD between 2014 and 2019 was performed. The crude prevalence rate of FECD was assessed and extrapolated to estimate the total case burden in the United States. The prevalence data were further compared between men and women and different racial groups. In addition, the economic burden was computed using inflation-adjusted direct costs of treatment to patients. The Medicare database included 25,432,700 patients older than 65 years. The national prevalence of FECD in this population cohort was calculated to be 1.12% in 2019. In 2019, FECD case burden in Medicare patients older than 65 years was 284,846 and total estimated FECD case count in the country in this age group was 591,226. FECD prevalence was significantly higher in women as compared to men during the 6-year period evaluated in this study. The intergroup comparison revealed that FECD prevalence in the White population was significantly higher than all other racial groups (P < 0.0001). The total inflation-adjusted economic burden of FECD in the United States in 2019 was USD 291.648 million and has increased from USD 243.998 million over the 6-year study period. The estimated prevalence of FECD in the individuals older than 65 years is 1.12% in the United States. FECD prevalence is significantly higher in women and White population compared with other ethnicities.
Identifiants
pubmed: 37906001
doi: 10.1097/ICO.0000000000003416
pii: 00003226-990000000-00402
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
Gain P, Jullienne R, He Z, et al. Global survey of corneal transplantation and eye banking. JAMA Ophthalmol. 2016;134:167–173.
Fuchs E. Dystrophia epithelialis corneae. Albrecht von Graefes Arch Ophthalmol. 1910;76:478–508.
Jun AS. One hundred years of Fuchs' dystrophy. Ophthalmology. 2010;117:859–860.e14.
Krachmer JH, Purcell JJ, Young CW, et al. Corneal endothelial dystrophy: a study of 64 families. Arch Ophthalmol. 1978;96:2036–2039.
Graves B. Report to the Lang Clinical Research Committee, Royal London Ophthalmic Hospital: a bilateral chronic affection of the endothelial face of the cornea of elderly persons with an account of the technical and clinical principles of its slit-lamp observation. Br J Ophthalmol. 1924;8:502–544.
Vedana G, Villarreal G, Jun AS. Fuchs endothelial corneal dystrophy: current perspectives. Clin Ophthalmol. 2016;10:321–330.
Ong Tone S, Kocaba V, Böhm M, et al. Fuchs endothelial corneal dystrophy: the vicious cycle of Fuchs pathogenesis. Prog Retin Eye Res. 2021;80:100863.
Hamill CE, Schmedt T, Jurkunas U. Fuchs endothelial cornea dystrophy: a review of the genetics behind disease development. Semin Ophthalmol. 2013;28:281–286.
Zoega GM, Fujisawa A, Sasaki H, et al. Prevalence and risk factors for cornea guttata in the Reykjavik Eye Study. Ophthalmology. 2006;113:565–569.
Eghrari AO, McGlumphy EJ, Iliff BW, et al. Prevalence and severity of fuchs corneal dystrophy in Tangier Island. Am J Ophthalmol. 2012;153:1067–1072.
Nagaki Y, Hayasaka S, Kitagawa K, et al. Primary cornea guttata in Japanese patients with cataract: specular microscopic observations. Jpn J Ophthalmol. 1996;40:520–525.
Kitagawa K, Kojima M, Sasaki H, et al. Prevalence of primary cornea guttata and morphology of corneal endothelium in aging Japanese and Singaporean subjects. Ophthalmic Res. 2002;34:135–138.
Aiello F, Gallo Afflitto G, Ceccarelli F, et al. Global prevalence of fuchs endothelial corneal dystrophy (FECD) in adult population: a systematic review and meta-analysis. J Ophthalmol. 2022;2022:3091695–3091697.
Minear MA, Li YJ, Rimmler J, et al. Genetic screen of African Americans with Fuchs endothelial corneal dystrophy. Mol Vis. 2013;19:2508–2516.
Louttit MD, Kopplin LJ, Igo RP, et al. A multicenter study to map genes for Fuchs endothelial corneal dystrophy: baseline characteristics and heritability. Cornea. 2012;31:26–35.
Afshari NA, Pittard AB, Siddiqui A, et al. Clinical study of Fuchs corneal endothelial dystrophy leading to penetrating keratoplasty: a 30-year experience. Arch Ophthalmol. 2006;124:777–780.
Zoega GM, Arnarsson A, Sasaki H, et al. The 7-year cumulative incidence of cornea guttata and morphological changes in the corneal endothelium in the Reykjavik Eye Study. Acta Ophthalmol. 2013;91:212–218.
Wilson SE, Bourne WM. Fuchs' dystrophy. Cornea. 1988;7:2–18.
Hogan MJ, Wood I, Fine M. Fuchs' endothelial dystrophy of the cornea. 29th Sanford Gifford Memorial lecture. Am J Ophthalmol. 1974;78:363–383.
Zhang X, Igo RP, Fondran J, et al. Association of smoking and other risk factors with Fuchs' endothelial corneal dystrophy severity and corneal thickness. Invest Ophthalmol Vis Sci. 2013;54:5829–5835.
Nealon CL, Halladay CW, Gorman BR, et al. Association between fuchs endothelial corneal dystrophy, diabetes mellitus, and multimorbidity. Cornea. 2023;42:1140–1149.
What's Medicare? | Medicare. Availabe at: https://www.medicare.gov/what-medicare-covers/your-medicare-coverage-choices/whats-medicare. Accessed June 5, 2023.
Project Description | Vision and Eye Health Surveillance System (VEHSS) | Vision Health Initiative (VHI) | CDC. Availabe at: https://www.cdc.gov/visionhealth/vehss/project/index.html. Accessed June 5, 2023.
Vision and Eye Health Surveillance System | Vision Health Initiative (VHI) | CDC. Availabe at: https://www.cdc.gov/visionhealth/vehss/index.html. Accessed June 6, 2023.
CPI Inflation Calculator. Availabe at: https://www.bls.gov/data/inflation_calculator.htm. Accessed June 6, 2023.
Dhaliwal DK, Chirikov V, Schmier J, et al. Cost burden of endothelial keratoplasty in fuchs endothelial dystrophy: real-world analysis of a commercially insured US population (2014-2019). Clin Ophthalmol. 2022;16:1055–1067.
Huh DD, Dun C, Fliotsos MJ, et al. Trends and surgeon variations in early regrafts after endothelial keratoplasty: analysis of the national Medicare data set. Cornea. 2023;42:1016–1026.
Borboli S, Colby K. Mechanisms of disease: Fuchs' endothelial dystrophy. Ophthalmol Clin North Am. 2002;15:17–25.
Gottsch JD, Zhang C, Sundin OH, et al. Fuchs corneal dystrophy: aberrant collagen distribution in an L450W mutant of the COL8A2 gene. Invest Ophthalmol Vis Sci. 2005;46:4504–4511.
Das A, Chaurasia S. Clinical profile and demographic distribution of Fuchs' endothelial dystrophy: an electronic medical record–driven big data analytics from an eye care network in India. Indian J Ophthalmol. 2022;70:2415–2420.
Afshari NA, Pittard AB, Siddiqui A, et al. Clinical study of Fuchs corneal endothelial dystrophy leading to penetrating keratoplasty: a 30-year experience. Arch Ophthalmol. 2006;124:777–780.
Magovern M, Beauchamp GR, McTigue JW, et al. Inheritance of Fuchs' combined dystrophy. Ophthalmology. 1979;86:1897–1923.
Cross HE, Maumenee AE, Cantolino SJ. Inheritance of Fuchs' endothelial dystrophy. Arch Ophthalmol. 1971;85:268–272.
Halilovic A, Schmedt T, Benischke A-S, et al. Menadione-induced DNA damage leads to mitochondrial dysfunction and fragmentation during rosette formation in Fuchs endothelial corneal dystrophy. Antioxid Redox Signal. 2016;24:1072–1083.
Liu C, Miyajima T, Melangath G, et al. Ultraviolet A light induces DNA damage and estrogen-DNA adducts in Fuchs endothelial corneal dystrophy causing females to be more affected. Proc Natl Acad Sci USA. 2020;117:573–583.
Wang KJ, Jhanji V, Chen J, et al. Association of transcription factor 4 (TCF4) and protein tyrosine phosphatase, receptor type G (PTPRG) with corneal dystrophies in southern Chinese. Ophthalmic Genet. 2014;35:138–141.
Riazuddin SA, McGlumphy EJ, Yeo WS, et al. Replication of the TCF4 intronic variant in late-onset Fuchs corneal dystrophy and evidence of independence from the FCD2 locus. Invest Ophthalmol Vis Sci. 2011;52:2825–2829.
Nanda GG, Padhy B, Samal S, et al. Genetic association of TCF4 intronic polymorphisms, CTG18.1 and rs17089887, with Fuchs' endothelial corneal dystrophy in an Indian population. Invest Ophthalmol Vis Sci. 2014;55:7674–7680.
Kuot A, Hewitt AW, Griggs K, et al. Association of TCF4 and CLU polymorphisms with Fuchs' endothelial dystrophy and implication of CLU and TGFBI proteins in the disease process. Eur J Hum Genet. 2012;20:632–638.
Woodward MA, Hughes K, Ballouz D, et al. Assessing eye health and eye care needs among North American Native individuals. JAMA Ophthalmol. 2022;140:134–142.
Price MO, Feng MT, Price FW. Endothelial keratoplasty update 2020. Cornea. 2021;40:541–547.
Melles GRJ, Wijdh RHJ, Nieuwendaal CP. A technique to excise the descemet membrane from a recipient cornea (descemetorhexis). Cornea. 2004;23:286–288.
Heckenlaible NJ, Dun C, Prescott C, et al. Predictors of receiving keratoplasty for Fuchs' endothelial corneal dystrophy among Medicare beneficiaries. Ophthalmology. 2023;130:28–38.